-
Your selected country is
United States
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Researchers should determine the optimal concentration of this reagent for their individual applications.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- CF™ is a trademark of Biotium, Inc.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
Companion Products
The V7.1 monoclonal antibody specifically recognizes CD101 which is also known as P126 or Glu-Trp-Ile EWI motif-containing protein 101 (EWI-101). CD101 is encoded by IGSF2 (Immunoglobulin superfamily member 2) and belongs to the EWI (sharing a conserved glutamine-tryptophan-isoleucine motif) family within the Ig superfamily. CD101 is a ~135-140 kDa type I transmembrane glycoprotein that has a short cytoplasmic domain with potential phosphorylation sites and an extracellular region with seven immunoglobulin-variable (IgV)-like domains. CD101 is expressed as homodimers by granulocytes, monocytes, dendritic cells, and some T cells. Its expression by T cells may be upregulated upon activation through the CD3 complex. CD101 may play a role in TCR/CD3-dependent T-cell activation.
Development References (4)
-
Boumsell L, Hall KT, Freeman GJ, Benussan A. CD101 Workshop Panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:1033-1034.
-
Rivas A, Ruegg CL, Zeitung J, et al. V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies.. J Immunol. 1995; 154(9):4423-33. (Immunogen). View Reference
-
Ruegg CL, Rivas A, Madani ND, Zeitung J, Laus R, Engleman EG. V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene.. J Immunol. 1995; 154(9):4434-43. (Clone-specific: Immunofluorescence, Immunoprecipitation, Radioimmunoassay). View Reference
-
Soares LR, Rivas A, Ruegg C, Engleman EG. Differential response of CD4+ V7+ and CD4+ V7- T cells to T cell receptor-dependent signals: CD4+ V7+ T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigen.. Eur J Immunol. 1997; 27(6):1413-21. (Clone-specific: Inhibition). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.